Celltrion Healthcare, 1,775,761 Shares Net Sold by Foreigners in Last 5 Days... Stock Price at 104,700 KRW (-0.95%)

As of 9:30 AM on the 8th, Celltrion Healthcare is trading at 104,700 KRW, down 0.95% from the previous day. The trading volume is 521,481 shares, which is about 15.51% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On July 7, Lee Dong-geon, a researcher at Shinhan Financial Investment, stated, "EMA CHMP has recommended approval for the additional indication of Remsima SC for IBD. Despite steady stock price increases since the beginning of the year, the launch effects of Truxima and Remsima SC are expected to drive continuous quarterly earnings growth. According to media reports yesterday, One Equity Partners (OEP) has begun demand forecasting to sell all remaining shares of approximately 3.16 million shares through a block deal. Given the continued strong performance, this is viewed as a positive factor for the stock by reducing overhang pressure." He set the target price for Celltrion Healthcare at 140,000 KRW.

Over the past five days, individual investors have net purchased 1,473,502 shares of Celltrion Healthcare, while foreigners and institutions have net sold 1,775,761 shares and net purchased 266,327 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.